Saturday 17 October 2026
Export CGC’s income statement to Excel — free account
Canopy Growth Corporation
CGC Healthcare Drug Manufacturers Specialty & Generic
Canopy Growth Corporation’s revenue for fiscal 2026 (year ended March 2026) was $206.0 million, up 6.55% from fiscal 2025. In the quarter to June 2026, revenue grew 12.4%, EPS grew 87.5%, free cash flow fell 117.6% and total debt fell 18.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, operating cash flow growth for three.
0.71
0.03
−4.05%
Follow CGC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.89 | 1.37 | 1.98 | 2.01 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.21) | (20.96) | (32.50) | (30.58) | |
P/B ratio |
0.81 | 0.56 | 0.72 | 0.75 | |
Price to Tangible BV |
1.02 | 0.71 | 0.87 | 0.91 | |
EV/Sales |
1.54 | 0.90 | 1.44 | 1.73 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.77) | (3.99) | (5.02) | (5.55) | |
EV/FCF |
(5.40) | (3.65) | (4.56) | (5.09) | |
Quick Ratio |
2.30 | 2.56 | 4.16 | 4.08 | |
Current Ratio |
3.04 | 3.34 | 5.34 | 5.50 | |
Net Debt/EBITDA |
8.40 | 1.57 | 8.57 | 9.92 | |
Debt/Assets |
21.76% | 20.86% | 20.34% | 21.33% | |
Debt/Equity |
0.35 | 0.33 | 0.30 | 0.31 | |
Asset Turnover |
0.29 | 0.28 | 0.25 | 0.24 | |
Operating CF/Net income |
1.72 | 0.12 | 0.27 | 10.99 | |
Capex/Depreciation |
(0.07) | (0.13) | (0.21) | (0.16) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
51.23% | 59.82% | 60.81% | 57.44% | |
Intangible Assets out of Total Assets |
0.13 | 0.13 | 0.11 | 0.12 | |
Share Based Compensation of Revenue |
1.67% | 2.08% | 1.16% | 3.01% | |
Graham Net Nets |
0.16 | 0.28 | 0.32 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(46.77%) | (61.51%) | (113.54%) | (133.86%) | |
Free Cash Flow Yield |
(15.12%) | (17.83%) | (15.95%) | (16.94%) | |
Revenue per Share |
0.14 | 0.17 | 0.15 | 0.18 | |
Operating CF per Share |
(0.04) | (0.05) | (0.04) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.05) | (0.04) | (0.05) | |
Cash per Share |
0.58 | 0.90 | 0.78 | 0.80 | |
Shareholders Equity per Share |
1.18 | 1.69 | 1.57 | 1.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.18 | 1.69 | 1.57 | 1.95 | |
Free Cash Flow |
(18.60) | (14.34) | (13.45) | (14.15) | |
Working Capital |
245.30 | 268.55 | 305.84 | 264.74 | |
Capital Expenditures |
(0.53) | (0.83) | (1.33) | (1.07) | |
Net Current Asset Value |
65.78 | 78.41 | 126.71 | 81.29 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
33.47 | 32.10 | 29.19 | 25.09 | |
Average Payables |
19.04 | 21.98 | 17.49 | 13.31 | |
Average Inventory |
72.72 | 74.63 | 70.27 | 70.18 | |
Average Assets |
725.72 | 734.64 | 812.48 | 839.95 | |
Average Common Equity |
425.46 | 427.54 | 483.13 | 453.93 |
Columns are period end dates